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Objective: To determine whether sentinel lymph node biopsy (SLNB) is associated with 
improved disease-specific survival among elderly patients with intermediate-thickness 
melanoma 
Design: Retrospective cohort study of prospectively-maintained tumor registry  
Setting: Single institution tertiary care center 
Patients: Adults ≥ 70 years of age, who underwent surgical intervention for melanoma from 
2000-2013 
Main Outcome Measures: The primary outcomes were overall survival (OS) and disease-free 
survival (DFS).  Other clinicopathologic variables measured included age, gender, anatomic 
site, histologic type, tumor thickness, presence of adverse features, receipt and result of SLNB, 
and receipt of completion lymph node dissection (CLND). 
Results: Ninety-one patients (mean age 80 years, 54% male) underwent wide excision of an 
intermediate-thickness melanoma.  Forty-nine patients (54%) received a SLNB.  Seven of these 
biopsies (14%) were positive, and five patients (71%) went on to receive CLND.  Five-year OS 
was 41% in patients who did not receive SLNB and 52% in patients who did receive SLNB (Fig. 
1A).  However, 5-year DFS was 79% in patients who did not receive SLNB and 77% in patients 
who did receive SLNB (Fig. 1B). 
Conclusions: Among elderly patients with intermediate-thickness melanoma, patients who 
received SLNB had higher 5-year OS than those who did not receive SLNB.  However, the 5-
year DFS is similar between the two groups, which suggests that the OS differences are related 
to non-melanoma factors.   Routine SLNB for intermediate-thickness melanoma patients may 
not significantly change the outcome for this age group, and clinical decision-making should 
consider individual patient comorbidities and goals of care. 
 
Figure 1. Survival of patients with intermediate-thickness melanoma 
 
Kaplan-Meier curves of overall (A) and disease-free (B) survival, among patients with 
intermediate-thickness melanoma, who either did receive sentinel lymph node biopsy (SLNB+) 
or did not receive sentinel lymph node biopsy (SLNB-). 
